DB16327InvestigationalGene Therapies
Sepofarsen is under investigation in clinical trial NCT03913143 (A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)).
- Code names
- QR-110
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 23, 2025
Which companies are running trials of Sepofarsen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account